Shares of Biohaven stock opened at $37.24 on Thursday. The business’s 50 day simple moving average is $38.20 and its two-hundred day simple moving average is $42.75. The stock has a market ...

Shares of BHVN opened at $29.87 on Wednesday. Biohaven has a 1-year low of $26.80 and a 1-year high of $62.21. The stock has a market cap of $3.02 billion, a PE ratio of -3.19 and a beta of 1.27 ...

In this article, we are going to take a look at where Biohaven Ltd. (NYSE:BHVN) stands against other stocks with heavy insider buying in 2025. Insider trading is often seen as an important ...

Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. The registrational study assessed BHV-7000, a drug designed to selectively activate Kv7.2/Kv7.3 ...

Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $63 from $69 and keeps an Overweight rating on the shares. Biohaven reported Q4 earnings on March 3 and provided “mixed ...

NEW YORK, NY / ACCESS Newswire / March 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.") (NYSE:BHVN) concerning possible ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Thursday, shares of Biohaven Ltd (Symbol: BHVN) entered into oversold territory, hitting an RSI reading of 29. ...

We recently published a list of 12 Stocks with Heavy Insider Buying in 2025. In this article, we are going to take a look at where Biohaven Ltd. (NYSE:BHVN) stands against other stocks with heavy ...

Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of total IgG, differentiating Biohaven's new small-molecule class of degraders from the monoclonal ...

Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal antibody FcRn ...